Biothera Pharmaceuticals, Inc

www.biothera.com

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that enhances the efficacy of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. The Company has clinical research agreements with Merck to evaluate Imprime PGG and Merck’s KEYTRUDA (pembrolizumab) in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

news image

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More

Medical, Industry Outlook

INTRODUCING THE ANBIO ADL I1910: AN ELEGANT CLIA ANALYZER FOR COMPREHENSIVE CLINICAL TESTING

PRNewswire | July 12, 2023

news image

Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics. With its cutting-edge technology and versatile capabilities, the ADL i1910 offers a comprehensive range of qualitative and quantitative testing options for analytes in human serum, plasma, whole blood, and urine samples. The ADL i1910 utilizes a direct chemilumines...

Read More

Industrial Impact

NOVO HOLDINGS LEADS US$21M SERIES A FINANCING IN BIOMILQ

Novo Holdings | October 21, 2021

news image

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estim...

Read More

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

news image

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More
news image

Medical

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More
news image

Medical, Industry Outlook

INTRODUCING THE ANBIO ADL I1910: AN ELEGANT CLIA ANALYZER FOR COMPREHENSIVE CLINICAL TESTING

PRNewswire | July 12, 2023

Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics. With its cutting-edge technology and versatile capabilities, the ADL i1910 offers a comprehensive range of qualitative and quantitative testing options for analytes in human serum, plasma, whole blood, and urine samples. The ADL i1910 utilizes a direct chemilumines...

Read More
news image

Industrial Impact

NOVO HOLDINGS LEADS US$21M SERIES A FINANCING IN BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estim...

Read More
news image

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us